NR4A1 and triple-negative breast carcinoma: Subgroup analyses showed that locoregional therapy did not improve overall survival for any subtype, including triple-negative breast cancer (HR, 1.4; 95%CI, 0.50–3.91), hormone-receptor-positive cancer (HR, 0.96; 95%CI, 0.65–1.43) and HER2-positive cancer (HR, 0.93; 95%CI, 0.68–1.28).